文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

一种新型生物标志物组合可在脓毒症症状出现前预警其发生

A Novel Combination of Biomarkers to Herald the Onset of Sepsis Prior to the Manifestation of Symptoms.
PubMed 文献 · Shock · 2018-01-01
一句话结论综述提出降钙素原(PCT)、白介素-6(IL-6)与可溶性髓系细胞触发受体-1(sTREM-1)三联检测可能有助于在脓毒症症状出现前作出诊断,但尚无临床验证数据。

脓毒症在美国每年导致超过20万患者死亡、医疗花费超过200亿美元,其机制与其他炎症状态相同,临床上常因混淆而误诊。现有生物标志物检测只能评估脓毒症的严重程度与死亡风险,尚无单一检测能在症状出现前预测脓毒症以实现抢先治疗与监测。该综述总结当前脓毒症生物标志物用于预后判断 morbidity 与 mortality 的使用情况,认为现行单一标志物及联合标志物检测均缺乏特异性与准确性,不符合当前患者需求。综述讨论促炎细胞因子、一般炎症标志物及髓系细胞特异(因而感染特异)蛋白,最终建议采用PCT、IL-6与sTREM-1三联检测以在症状出现前诊断脓毒症。

要点

  • 综述指出当前单一生物标志物及联合标志物检测对脓毒症均缺乏特异性与准确性,不符合当前患者需求。
  • 综述最终建议采用降钙素原(PCT)、白介素-6(IL-6)与可溶性髓系细胞触发受体-1(sTREM-1)三联检测,以在症状出现前诊断脓毒症。
  • 现有生物标志物检测只能评估脓毒症的严重程度与死亡风险,尚无能在症状出现前预测脓毒症的单一检测。
  • 脓毒症机制与其他炎症状态相同,临床易因混淆而误诊。
  • 该三联检测目前仅为综述提出的设想,文中未报告临床验证数据。

研究设计与关键结果

  • 综述总结当前脓毒症生物标志物用于预后判断 morbidity 与 mortality 的使用情况,并否定现行单一标志物及联合标志物检测的特异性与准确性。
  • 综述讨论促炎细胞因子、一般炎症标志物及髓系细胞特异(因而感染特异)蛋白三类标志物。
  • 综述最终建议采用降钙素原(PCT)、白介素-6(IL-6)与可溶性髓系细胞触发受体-1(sTREM-1)三联检测以在脓毒症症状出现前作出诊断。

证据类型、等级与局限

  • 证据类型:综述。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者建议采用PCT、IL-6与sTREM-1三联检测以在脓毒症症状出现前作出诊断。
  • 原文指出尚无单一检测能在症状出现前预测脓毒症以实现抢先治疗与监测。
  • 原文指出当前单一生物标志物及联合标志物检测均缺乏特异性与准确性,不符合当前患者需求。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「适用人群与场景」「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Sepsis, which kills over 200,000 patients and costs over $20 billion in the United States alone, presents a constant but preventable challenge in the healthcare system. Among the more challenging problems that it presents is misdiagnosis due to conflation with other inflammatory processes, as its mechanisms are identical to those of other inflammatory states. Unfortunately, current biomarker tests can only assess the severity and mortality risk of each case, whereas no single test exists that can predict sepsis prior to the onset of symptoms for the purpose of pre-emptive care and monitoring. We propose that a single test utilizing three, rather than two, biomarkers that appear most quickly in the blood and are the most specific for sepsis rather than trauma, may improve diagnostic accuracy and lead to lessened patient morbidity and mortality. Such a test would vastly improve patient outcomes and quality of life, prevent complications for sepsis survivors, and prevent hospital readmissions, saving the American healthcare system money. This review summarizes the current use of sepsis biomarkers to prognosticate morbidity and mortality, and rejects the current single-biomarker and even combination biomarker tests as non-specific and inaccurate for current patient needs/pro-inflammatory cytokines, general markers of inflammation, and proteins specific to myeloid cells (and therefore to infection) are discussed. Ultimately, the review suggests a three-biomarker test of procalcitonin (PCT), interleukin-6 (IL-6), and soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) to diagnose sepsis before the onset of symptoms.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Dolin HH, Papadimos TJ, Stepkowski S, et al. A Novel Combination of Biomarkers to Herald the Onset of Sepsis Prior to the Manifestation of Symptoms. Shock. 2018. PMID: 29016484. doi:10.1097/SHK.0000000000001010

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。